Quell Therapeutics Raises $156 million in Oversubscribed Series B Financing to Advance its Pioneering Multi-Modular Engineered T Regulatory (Treg) Cell Therapy Pipeline and Platform

- Series B co-led by Jeito Capital, Ridgeback Capital Investments, SV Health Investors and Fidelity Management & Research Company LLC, alongside founding investor Syncona and includes a broad

Related Keywords

Boston ,Massachusetts ,United States ,Paris ,France General ,France ,United Kingdom ,London ,City Of ,British ,Eleanor Perkin ,Frazer Hall ,Luke Henry ,Iain Mcgill ,Martin Murphy ,Dwayne Holman ,Kostenloser Wertpapierhandel ,Phouman Ashrafian ,Christina Tartaglia ,Linkedin ,Stern Investor Relations Inc ,Sv Health Investors ,Syncona Investment Management ,Tekla Capital Management ,Fidelity Management Research Company ,Syncona Ltd ,Prnewswire Quell Therapeutics Ltd ,Jeito Capital ,Ridgeback Capital Investments ,Fidelity Management ,Research Company ,Therapeutics Ltd ,British Patient Capital ,Future Fund ,Janus Henderson Investors ,Monashee Investment Management ,Chief Executive Officer ,Rachel Mears ,Jeffrey Long Mcgie ,Managing Director ,Ridgeback Capital ,Managing Partner ,Syncona Investment Management Limited ,Chief Business ,Mark Swallow ,Investor Relations ,Aquell ,Herapeutics ,Raises ,Billion ,Oversubscribed ,Series ,Financing ,Advance ,Ioneering ,Ulti ,Odular ,Engineered ,Egulatory ,Greg ,Fell ,Therapy ,Pipeline ,Platform ,